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We attempted to identify deleted segments in two model tumor suppressor gene loci on chromosomes 13q14
and 17p13 that were associated with clonal expansion of in situ bladder preneoplasia using single nucleotide
polymorphisms (SNPs)-based whole-organ histologic and genetic mapping. For mapping with SNPs, the
sequence-based maps spanning approximately 27 and 5 Mb centered around RB1 and p53, respectively, were
assembled. The integrated gene and SNP maps of the regions were used to select 661 and 960 SNPs, which
were genotyped by pyrosequencing. Genotyping of SNPs was performed on DNA samples corresponding to
histologic maps of the entire bladder mucosa in human cystectomy specimens with invasive urothelial
carcinoma. By using this approach, we have identified deleted regions associated with clonal expansion of
intraurothelial neoplasia; which ranged from 0.001 to 4.3 Mb (average 0.67 Mb) and formed clusters of
discontinuous deleted segments. The high resolution of such maps is a prerequisite for future positional
targeting of genes involved in early phases of bladder neoplasia. This approach also permits analysis of the
overall genomic landscape of the involved region and discloses that a unique composition of noncoding DNA
characterized by a high concentration of repetitive sequences may predispose to deletions.
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Cancer develops via multiple, complex steps, many
of which precede the development of micro-
scopically recognizable preneoplastic conditions.1–3
Recent studies indicate that common human malig-
nancies, including bladder cancer, begin as clonal
in situ expansion of phenotypically normal cells,
which may form large plaques involving the affected
mucosa.4,5 Identification of chromosomal regions
and their target genes involved in the development
of such clinically and microscopically occult
preneoplastic lesions may provide valuable clues
to the incipient events of human carcinogenesis.6,7
Ultimately, the results could lead to the develop-
ment of novel markers for early cancer detection and
prevention.
We have previously reported the identification
of several putative tumor suppressor gene loci
involved in early preinvasive phases of human
bladder cancer.8–11 These loci were found by
searching for allelic imbalances using DNA hyper-
variable markers and a whole-organ histologic and
genetic mapping strategy developed in our labora-
tory. The ultimate identification of genes mapping to
the deleted regions was hampered by the low
resolution of the original recombination-based maps
and the absence of continuous genome sequence
maps, which were not available in the early phases
of the human genome project.
In this paper, we present the strategy that
combines whole-organ histologic maps and high-
resolution genetic mapping using single nucleotide
polymorphic (SNP) sites. It facilitates precise iden-Received 7 January 2005; revised and accepted 8 February 2005
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tification of deleted chromosomal regions and their
positional candidate genes associated with growth
advantage and clonal expansion of in situ preneo-
plasia.12–14 Here, we concentrate on the technologi-
cal aspects of this approach referred to as high-
resolution whole-organ mapping with SNPs and
present the pattern of losses associated with clonal
expansion of in situ bladder preneoplasia in two
model tumor suppressor gene loci (RB1 and p53).
Methods
Whole-Organ Histologic and Genetic Mapping
Whole-organ histologic and genetic mapping was
performed as described in our previous publica-
tions.8–11 In brief, each fresh cystectomy specimen,
taken from a patient who had bladder cancer, was
opened longitudinally along the anterior wall of the
bladder and pinned down to a paraffin block. The
entire mucosa was divided into 1 2 cm rectangular
samples and evaluated microscopically on frozen
sections. The tissue of interest was microdissected
from the frozen block, and cell suspensions were
prepared by mechanically scraping the urothelial
mucosa or gently shaking invasive tumor samples.
Only those specimens that yielded more than 90%
microscopically recognizable, intact urothelial, dys-
plasia of tumor were accepted for the study and used
for DNA extraction. The intraurothelial precancer-
ous changes were classified as mild, moderate, and
severe dysplasia of carcinoma in situ. The tumors
were classified according to the three-tier World
Health Organization histological grading system and
growth pattern (papillary vs nonpapillary).15 The
depth of invasion was recorded according to the
TNM (tumor–node–metastasis) staging system.16 In
this report, we present the data using two whole
maps of cystectomy specimens, which yield 62 and
40 DNA samples, respectively, and both contained
microscopically normal urothelium, preneoplastic
condition, in situ changes, and invasive cancer. In
both maps, a single focus of grade 3 nonpapillary
urothelial carcinoma invaded the muscularis pro-
pria and was accompanied by extensive in situ
precancerous lesions ranging from mild dysplasia to
carcinoma in situ.
Genotyping with SNPs
The positions of chromosomal regions associated
with an in situ clonal expansion mapping to 13q14
and 17p13 were initially identified by the whole-
organ histologic and genetic mapping strategy with
microsatellite markers. The recombination-based
deletional maps of these regions can be obtained at
www.mdanderson.org/departments/genomemaps/.
For high-resolution mapping with SNPs, the genome
sequence maps spanning approximately 27 and
5 Mb, corresponding to microsatellite defined re-
gions in 13q14 and 17p13, respectively, were
assembled. The positions of all currently defined
SNPs mapping within these regions (approximately
20 000 SNPs per region) were identified in the SNP
database (http://www.ncbi.nlm.nih.gov/SNP) and
integrated with the genome sequence maps. The
integrated gene and SNP maps were used to select
661 SNPs mapping within a 27-Mb segment around
RB1 and 960 SNPs mapping within a 5-Mb segment
around p53.
SNPs were genotyped by pyrosequencing meth-
ods using an automatic pyrosequencing instrument
PSQTM 96 (Pyrosequencing AB, Uppsala, Swe-
den).17,18 In brief, genomic DNA fragments contain-
ing SNPs were amplified by PCR with one of each
primer biotinylated at the 50-end. Single-stranded
DNA was isolated by streptavidin-coated magnetic
beads (Dynabeads M280, Dynal, Oslo, Norway). The
sequencing reaction mixture contained a single-
stranded DNA with sequencing primer annealed,
DNA polymerase, apyrase, luciferase, ATP sulfur-
ylase, adenosine 50-phosphosulfate, and luciferin.
The PCR and sequencing reactions were performed
on a TECAN robotic system (GENESIS workstation
Figure 1 Whole-organ histologic mapping, and molecular haplotyping with SNPs. (a–c) An example of molecular haplotyping with SNP
showing clonal allelic loss in multiple mucosal samples. (a) Sequence pyrograms of a polymorphic T/C residue showing a clonal loss of
C in areas of microscopically normal appearing urothelium, in situ preneoplastic conditions (HGIN, LGIN), and invasive carcinoma
(TCC). (b, c) Examples of sequence pyrograms with a T/C polymorphism in peripheral blood and a loss of C residue in a mucosal sample
from NU are shown in the upper panels. Corresponding histograms showing expected signals of nucleotide incorporation are shown in
the lower panels. (d–g) Molecular haplotyping of SNP showing a nonclonal loss of G or T residues in scattered mucosal samples. (d)
Sequence pyrograms of SNP showing a loss of T or G residues in scattered mucosal samples. (e–g) Examples of sequence pyrograms with
a G/T polymorphism in peripheral blood and random loss of T or G residues in individual mucosal samples are shown in the upper
panels. Corresponding histograms showing expected sequences of nucleotide incorporation signals of SNP with retention of both alleles
and loss of T or G residues are shown in the lower panels. (h) A histologic map of a cystectomy specimen with an outlined area of
mucosa, exhibiting clonal allelic loss of the SNP shown in (a). Note that the area of allelic loss forms a continuous plaque, implying that
it was associated with clonal expansion of an in situ preneoplasia. (i) A histologic map of cystectomy specimen with outlined areas of
mucosa involved by a nonclonal loss of the SNP shown in (d). The polymorphic nucleotide is underlined in sequence pyrograms and
their corresponding histograms. A negative control after exposure to the substrates of irrelevant nucleotides follows the polymorphic site
and is printed in red. PB, peripheral blood; NU, normal urothelium; LGIN, low-grade intraurothelial neoplasia; HGIN, high-grade
intraurothelial neoplasia; TCC, invasive transitional cell carcinoma. Histologic map code: NU, normal urothelium; MD, mild dysplasia;
MdD, moderate dysplasia; SD, severe dysplasia; CIS, carcinoma in situ; TCC invasive transitional cell carcinoma. For the purpose of
statistical analysis, intraurothelial precursor conditions were classified into two groups: low-grade intraurothelial neoplasia (mild to
moderate dysplasia, LGIN) and high-grade intraurothelial neoplasia (severe dysplasia and carcinoma in situ, HGIN).
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150). The sequence was determined from the
measured signal output of light upon nucleotide
incorporation. The resulting peaks were analyzed
using pyrosequencing software. A minimum 50%
signal intensity reduction from one of the poly-
morphic nucleotides as compared to the nontumor
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DNA of the same individual was used to identify a
haplotype defining allelic loss. The distributions of
losses identified in individual mucosal samples for
each SNP were subsequently superimposed over the
histologic maps of the entire cystectomy specimen.
Analysis of SNP-Based Haplotype Distribution
Patterns
The distribution patterns of allelic loss defined by
SNP-based haplotypes in relation to the develop-
ment and progression of in situ neoplasia were
analyzed in superimposed whole-organ histologic
and genetic maps by nearest neighbor and binomial
maximum likelihood algorithms as previously de-
scribed in detail.11 In brief, for statistical analyses,
the data were organized in 2 4 contingency tables
(fji, j¼ 1, 2; i¼ 1,y,4). The columns designated
whether the marker retained or lost heterozygocity
and the four grades represented the microscopic
status of the urothelium (D0, normal urothelium, D1,
low-grade intraurothelial neoplasia, D2, high-grade
intraurothelial neoplasia, and D3, transitional cell
carcinoma (TCC)). For statistical analysis, the in-
traurothelial precancerous changes were classified
into two major groups: low-grade intraurothelial
neoplasia (mild and moderate dysplasia, LGIN) and
high-grade intraurothelial neoplasia (severe dyspla-
sia and carcinoma in situ, HGIN).1
A nearest-neighbor analysis was performed on the
three-dimensional stacks of maps consisting of plots
with results of sequencing data for individual SNPs
by location on the histologic bladder and genome
sequence maps.19 A region with allelic loss was
considered a neighbor of another region of allelic
loss if the two were side by side in the same SNP
plot or above and below each other. A region with
allelic loss was also considered to be connected to
another region with allelic loss if there was a
continuous string of regions with allelic losses
between them. Since the bladder was laid open
and pinned flat, the left-most and right-most regions
were also neighbors.
The binomial maximum likelihood analysis was
performed in the same 2 4 contingency tables. The
maximum likelihood of the binomial distribution
was calculated for each SNP and urothelial status
(Di, i¼ 0,y,3) corresponding to normal urothelium
(NU), LGIN, HGIN, and TCC. The maximum like-
lihood for the binomial distribution was used to
determine whether a row of data was consistent
with a hypothesis of an unchanged (retention of
polymorphism) SNP by calculating the log like-
lihood with
li ¼ ln y
f1i
i ð1  yiÞf2i
y^f1ii ð1  y^iÞf2i
 !
for the null hypothesis H0, where y¼ yi, and y¼
f1i/(f1iþ f2i) is the maximum likelihood estimate of
SNP with retention of polymorphism. Two times the
negative of the log likelihood, 2li, is asymptotically
w2 with 1 degree of freedom, w2(1). This expression
can be written as
2li ¼2 lnð10Þlog10
y^f1ii ð1  y^iÞf2i
yf1ii ð1  yiÞf2i
 !
¼2 lnð10ÞLODðy^i :yiÞ
where LOD(y^i:yi) is the LOD-score function evalu-
ated at yI.20 Each row of the table for which 2li, has
approximate w2(1) can be tested separately (strin-
gency level 1) or all rows for diagnosis Di and more
advanced (Di,y, D3) can be combined (stringency
level 2) to get
f1iþ ¼
X3
j¼i
f1j
f2iþ ¼
X3
j¼i
f2j
Figure 2 Whole-organ mapping based on allelotyping of SNPs and assembly of three-dimensional display of allelic losses on
chromosome 13q14 in a single cystectomy specimen. (a) Genome sequence map of a 27.3-Mb region on chromosome 13q14
(www.mdanderson.org/departments/genomemaps/). The positions of hypervariable DNA markers and positions of the known or
predicted genes are depicted by the bars on the left-hand side of the map. The bars on the right-hand side of the map designate the
positions of all informative (polymorphic) SNPs identified in peripheral blood of the same patient. Monomorphic (noninformative) SNPs
are not shown. (b) Map of deleted segments depicted by red bars. Their predicted borders are defined by the nearest flanking SNPs that
retained polymorphism in all mucosal samples (see Figure 4). The positions of SNPs with allelic loss are shown on the right-hand side,
and their distribution patterns in bladder mucosa are depicted by the shaded blocks in c. (c) Three-dimensional display of allelic losses
depicted by shaded blocks in relation to the distribution of TCC and their association with in situ preneoplastic lesions displayed in the
whole-organ histologic map of a cystectomy specimen at the bottom of the diagram in (d). The SNPs with loss of polymorphism are
numbered consecutively 1–15. (d) Graphic representation of histologic map of cystectomy specimen with the distribution of in situ
preneoplastic lesions that progressed to invasive TCC. Histologic map code is identical to the code shown in Figure 1. (e) Summary of
binomial maximum likelihood analysis testing the relationship between loss of SNP polymorphism and progression of urothelial
neoplasia from in situ precursor conditions to invasive TCC. Cumulative LOD scores for SNPs with loss of polymorphism were calculated
at variable y¼ (0.01, 0.5, and 0.99) and tested against Tmax. The significance of clonal losses was analyzed for normal urothelium (NU),
low-grade intraurothelial neoplasia (LGIN), high-grade intraurothelial neoplasia (GHIN), and TCC. To simplify the data, stringency 1
calculations are presented only. The patterns of significant LOD scores are as described in Methods. The SNPs with loss of polymorphism
are numbered consecutively from 1 to 15 as depicted in (c). Note the significant pattern of LOD scores typically parallel to the high Tmax
values (J, LOD scoreo3;K, LOD scoreZ3). A cluster of three discontinuous segments of allelic loss associated with clonal expansion,
which form overlapping large plaques, not only involving microscopically recognizable in situ preneoplastic lesions but also extending
into areas of microscopically normal urothelium of bladder mucosa, was identified. The segments were defined by clusters of
neighboring SNP with clonal loss of polymorphism as shown by brackets on the right-hand side of the three-dimensional diagram.
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LODðy^iþ :yiþÞ ¼ log10
y^f1iþiþ ð1  y^iþÞf2iþ
yf1iþi ð1  yiþÞf2iþ
 !
which is also w2(1) after adjustment by 2 ln(10)¼
4.605. Because the maximum likelihood estimates
for the individual rows are usually different from
each other, the sum of the LOD scores and the sum
of the w2’s were greater than the combined statistics.
A w2 test for heterogeneity was appropriate to test
the combined estimate. Usually yi¼ 0.5 is used to
test linkage in familial disorders with meiotic
segregation of the phenotype.20 In reference to
sporadic cancer and especially when populations
of tested cells represent sequential stages of the
process with mitotic transmission of the phenotype,
the null hypothesis is more appropriately verified
at y differing from 0.5. For example, a value of
0.99 is more appropriate if the SNP retains poly-
morphism in the tissue, and a value of 0.01 is
more appropriate for determining whether the
SNP has lost polymorphism in the later stages of
the process, that is, invasive carcinoma. The pattern
of LOD scoresZ3 at y¼ 0.01 or 0.99 and LOD
scoreso3 at y¼ 0.5 for the same SNP was signifi-
cant. The strongest association between an SNP with
loss of polymorphism and neoplasia is when a LOD
score is Z3 at y¼ 0.99 and 0.5 and o3 at y¼ 0.01.
The use of binomial likelihood analysis and LOD
scores in our study is not the same as that commonly
used in linkage of familial genetic predispositions
for diseases. Here it is intended to be used in its
generic mathematical sense as likelihood tests of
events.20
Analysis of Genome Sequences
We analyzed the genome sequences spanning
the 27 and 4 Mb around RB1 and p53, respectively.
The genomic maps contained the positions of
all known and predicted genes, SNPs, and non-
LTR repeats integrated with the positions of
deleted regions defined by SNP-based haplotypes
from superimposed whole-organ histologic and
genetic maps. We concentrated on those deleted
regions that showed association with an in situ
clonal expansion of preneoplastic urothelial
cells and analyzed their CpG island and gene
contents as well as the frequency of non-LTR
repeats.
First, visual investigations of genomic maps
and deleted regions suggested that the segments
of deletions associated with in situ clonal expan-
sions may contain a high density of non-LTR
repeats. In order to verify this observation, we
started with the null hypothesis that location of
the deletions was independent of the repeat
sequences density. We tested this hypothesis
by analyzing the densities of repeats at fixed
width windows centered at the informative SNPs.
The repeat sequences density was defined as the
number of repeat sequences base pairs in a fixed
width window. The width of this window was
proportional to the spacing between informative
SNPs. The median distance between informative
SNPs of approximately 27 kB suggested an optimal
window of 13.5 kB on either side of the informative
SNP. In the second step, we ranked all repeat
sequences according to the number of base pairs
and Wilcoxon’s test was used to analyze the
difference in density of repeats around SNPs
showing loss associated with plaque-like clonal
expansion, SNPs showing scattered nonclonal
pattern of loss and with informative SNPs showing
retention of polymorphism. Similar analyses
were performed to test the relationship between
densities of CpG islands, gene content, and the
pattern of allelic loss defined by SNPs (data not
shown).
Figure 3 Whole-organ mapping based on allelotyping of SNPs and assembly of three-dimensional display of allelic losses on
chromosome 17p13 in a single cystectomy specimen. (a) Genome sequence map of a 4.27-Mb region on chromosome 17p13
(www.mdanderson.org/departments/genomemaps/). The positions of hypervariable DNA markers and positions of the known or
predicted genes are depicted by the bars on the left side of the map. The bars on the right side of the map designate the positions of all
informative (polymorphic) SNPs identified in the peripheral blood of the same patient. Monomorphic (noninformative) SNPs are not
shown. (b) Map of the deletions designated by vertical red bars. Their predicted borders were defined by the nearest flanking SNPs,
which retained polymorphism in all mucosal samples (see Figure 4). The bars on the right side designate the positions of SNPs with
allelic loss. Their distribution patterns in bladder mucosa are depicted by the shaded blocks in c. (c) Three-dimensional display of allelic
losses depicted by shaded blocks in relation to the distribution of transitional cell carcinoma (TCC) and their association with in situ
preneoplastic lesions. (d) Graphic representation of histologic map of cystectomy specimen with the distribution of in situ preneoplastic
lesions that progressed to invasive TCC. Histologic map code is identical to the code shown in Figure 1. (e) Summary of binomial
maximum likelihood analysis testing the relationship among loss of SNP polymorphism and progression of urothelial neoplasia from in
situ precursor conditions to invasive TCC. Cumulative LOD scores for SNPs with loss of polymorphism were calculated at variable y
¼ (0.01, 0.5, and 0.99) and tested against Tmax. The significance of clonal losses was analyzed for normal urothelium (NU), low-grade
intraurothelial neoplasia (LGIN), high-grade intraurothelial neoplasia (GHIN), and TCC. To simplify the data, stringency 1 calculations
are presented only. The patterns of significant LOD scores are as described in Methods. Note that the significant pattern of LOD scores
typically paralleled high Tmax values (J, LOD score o3; K, LOD score Z3). A cluster of two discontinuous segments of allelic loss
associated with clonal expansion, which form overlapping large plaques, not only involving microscopically recognizable in situ
preneoplastic lesions but also extending into areas of microscopically normal urothelium of bladder mucosa was identified. The
segments were defined by clusters of neighboring SNP with the loss of polymorphism as shown by brackets on the right side of the three-
dimensional diagram.
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Results
For mapping with SNPs, the sequence-based maps
spanning approximately 27 and 5 Mb centered
around RB1 and p53, respectively, were assembled.
The integrated gene and SNP maps of the regions
were used to select 661 and 960 SNPs, which were
genotyped by pyrosequencing. Genotyping of SNPs
was performed in three sequential steps on DNA
samples corresponding to histologic maps of the
entire bladder mucosa in human cystectomy speci-
mens with invasive urothelial carcinoma. Initially,
all selected SNPs of normal genomic DNA were
sequenced. In the next step, those SNPs that
exhibited polymorphism were tested on representa-
tive DNA samples corresponding to invasive transi-
tional cell carcinoma of the bladder (TCC). In the
final step, those SNPs that showed allelic loss were
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tested on all mucosal samples of the same cystec-
tomy specimen. The distribution of allelic loss for
each SNP was subsequently superimposed over the
histologic map of the entire organ. The borders of
deleted segments were defined by the nearest
flanking SNPs that retained polymorphism in all
mucosal samples. The allelic loss was determined
by the comparison of the sequences of the mucosal
and tumor DNA samples to the sequences of
nontumor DNA from the same patient. Clonal loss
was defined as the loss of the same polymorphic
nucleotide in multiple mucosal samples. Nonclonal
loss was defined as the loss of signal interchange-
ably corresponding to both residues of the poly-
morphic SNP in different mucosal samples.
The initial testing of 661 and 960 SNPs of
peripheral blood samples selected for mapping of
13q14 and 17p13 regions identified 101 and 187
polymorphic SNPs mapping to 27- and 4-Mb
segments containing RB1 and p53, respectively.
Subsequent testing of the informative polymorphic
SNPs in representative DNA samples corresponding
to invasive TCC identified 15 and 11 haplotypic
SNPs defining allelic loss in 13q14 and 17p13,
respectively. These SNPs were tested on all mucosal
samples of two cystectomy specimens. By super-
imposing the distribution of allelic losses over
histologic maps of the entire bladder mucosa, we
identified two basic distribution patterns of losses:
scattered and plaque-like (Figure 1). The scattered
foci of allelic losses in individual samples of bladder
mucosa were typically nonclonal and involved both
polymorphic residues of the SNP. In contrast,
plaque-like losses were clonal, involving large areas
of bladder mucosa with various precancerous con-
ditions and typically extending to normal appearing
urothelium. Such large clonal plaques of allelic loss
were statistically significantly associated with pro-
gression of in situ preneoplasia to invasive TCC as
revealed by binomial likelihood analysis. This
association implied that the loss was responsible
for growth advantage, which resulted in in situ
expansion of a preneoplastic clone. The deleted
regions associated with clonal expansion spanned
from 0.001 to 4.3 Mb (average 0.67 Mb) and formed
clusters of discontinuously deleted segments sepa-
rated by nondeleted regions (Figures 2 and 3). In
some instances, the flanking SNPs disclosed allelic
loss restricted to an individual mucosal sample, a
reflection of the instability of regions contiguous to
deleted segments (Figure 4).
A cluster of deletions associated with an in situ
clonal expansion in 13q14 involved approximately
13.97 Mb and consisted of four deleted segments
spanning 0.79, 0.68, 1.91, and 4.68 Mb. These
segments contained 7, 8, 9, and 10 positional
candidate genes, respectively, which might lead to
a growth advantage for a preneoplastic clone. The
model tumor suppressor gene RB1 mapped to the
deleted segment between 46.35 and 47.03 Mb (Fig-
ure 5). A similar cluster of deletions that consisted
of two deleted segments spanning 0.12 and 0.05 Mb
was identified 0.8 Mb telomerically to p53 in the
17p13 region. These two segments contained 12 and
five positional candidate genes, respectively, which
might also be relevant for growth advantage of a
preneoplastic clone.
Visually, the segments of deletions associated
with growth advantage and in situ clonal expan-
sion of preneoplastic urothelial cells contained a
significantly higher concentration of repetitive
sequences as compared to the nondeleted segments
and deletions, which formed scattered nonclonal
random mucosal foci (Figures 5 and 6). The
statistical analysis confirmed this impression and
disclosed that for chromosome 17 the segments of
allelic loss associated with a plaque-like clonal
expansion of preneoplastic clone involving large
areas of bladder mucosa contained a significantly
higher concentration of non-LTR repeats as com-
pared to the regions with retention of polymorphism
and regions, which showed nonclonal loss in the
form of scattered independent foci (Table 1 and
Figure 7). No such relationship could be found for
allelic loss on chromosome 13. Similar analyses of
CpG island and gene content did not reveal any
relationship between their densities and positions of
deleted segments (data not shown).
Discussion
Whole-organ histologic and genetic mapping facili-
tated the analysis of the relationship between allelic
loss and disease development from morphologically
normal urothelium through microscopically recog-
Figure 4 Clusters of clonal and nonclonal loss and their association with progression of bladder neoplasia. (a) SNPs pyrograms showing
nucleotide incorporation signals of SNPs in peripheral blood and corresponding mucosal samples. Pyrograms 1, 4, 5, and 7 correspond to
flanking SNPs, which show retention of polymorphism in all mucosal samples. Pyrograms 2 and 6 show the loss of the same allele in
multiple mucosal samples that form a continuous plaque involving a large area of bladder mucosa, while pyrogram 3 shows nonclonal
loss of SNP alleles in scattered mucosal areas. (b) Two discontinuous segments of deleted regions on chromosome 17 are depicted by
shadowed areas spanning 0.12 and 0.05 Mb, respectively. (c) The positions of all known and predicted genes within and around deleted
regions are depicted by bars on the left side of the map. The positions of the informative SNPs are designated by the bars on the right side
of the map. The sites in the bladder mucosa that were the sources of SNPs showing loss of polymorphism are connected to their
respective areas depicted in d. (d) Histologic map of cystectomy specimen. Areas outlined by the solid and dashed lines show clonal loss
of their corresponding SNPs, which formed a large plaque in the bladder mucosa. Areas outlined by the dotted line show nonclonal loss
of polymorphism in separate mucosal areas. (e) Representative microscopic samples of NU, precursor in situ conditions, and TCC are
shown. Note the increasing nuclear atypia and architectural disorder as intraurothelial precursor conditions advanced from LGIN to
HGIN and invasive stromal growth in TCC. Solid black bars within photomicrographs indicate 50mm.
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nizable intraurothelial lesions to invasive disease in
the entire mucosa of the resected organ. We
precisely identified those losses that are associated
with the in situ clonal expansion and are likely
significant for the incipient phases of bladder
carcinogenesis. Specifically, we identified clusters
of discontinuous loss mapping to 13q14 and 17p13
containing model suppressor genes RB1 and p53.
The high density of SNP markers permitted us to
narrow the deleted segments from 4.6 Mb to
below 0.1 Mb scale and disclosed that loses repre-
sented clusters of discontinuous segments ranging
in size from 0.1 to 4.6 Mb separated by nondeleted
regions.
The strategy presented here is not only important
for identifying positional candidate genes that may
provide growth advantage for a preneoplastic clone,
but for also permiting the analysis of the overall
genomic landscape of the involved regions. Such
an analysis disclosed that the deleted regions
associated with clonal expansion of preneoplasia
contained a high concentration of repetitive
Figure 5 Genomic organization and deletions of 10-Mb region around RB1. (a) Distribution of CpG islands and genes in a 100-kb
window. (b) Distribution of all non-LTR repetitive sequences in a 100-kb window: (c) Expanded view of the 1.6-Mb region around RB1
showing the positions of repetitive sequences and genes. Black bars in (a) and (b) depict the positions of three deleted segments
associated with in situ clonal expansion of urothelial cells identified by SNP-based whole-organ mapping shown in Figure 2. Shaded
areas in (c) and (d) depict a deleted segment containing eight genes including RB1. Note that the deleted segments shown in (a) and (b)
overlap with regions containing high concentrations of repetitive sequences.
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sequences. This, in turn, suggests that the unique
composition of noncoding DNA in the regions may
predispose the genome to instability and allelic
imbalance. The evidence provided by our study
implies that the genes located in deleted regions
may be responsible for growth advantage of in situ
preneoplasia and the high content of repetitive
sequences in these regions predisposed to deletions
is circumstantial and has to be elucidated by
functional studies. In summary, the strategy pre-
sented in this communication permits precise
identification of deleted chromosomal regions asso-
ciated with clonal expansion of preneoplasia. Such
maps performed on a whole-genome scale will be
critical for future specific studies on mechanisms
initiating carcinogenesis.
Figure 6 Genomic organization and deletions of 10-Mb region around TP53. (a) CpG islands and genes in a 100-kb window. (b) All non-
LTR repetitive sequences in a 100-kb window. (c) Expanded view of the 0.4 Mb region located telomerically to TP53 showing the
positions of repetitive sequences and genes. Black bars in (a) and (b) depict the positions of two deleted segments associated with in situ
clonal expansion of urothelial cells identified by SNP-based whole-organ mapping shown in Figure 3. Shaded areas in (c) and (d) depict
two deleted segments containing 12 and 5 genes, respectively. Note that the deleted segments are associated with high concentrations of
repetitive sequences, marked in (c) by the brackets.
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